Development and validation of a quasi-quantitative bioassay for neutralizing antibodies against CP-870,893

Journal of Immunotoxicology

Volumn 3, Issue 3, 2006, Pages 157-164

  Baltrukonis, Daniel J ^a   Finco Kent, Deborah ^a   Kawabata, Thomas T ^a   Poirier, Martin ^b   LeSauteur, Lynne ^b  

^a PFIZER INC   (United States)

^b CHARLES RIVER LABORATORIES   (United States)

Author keywords

Assay validation; Bioassay; CP 870,893; Daudi cell line; Neutralizing antibody

Indexed keywords

CD40 ANTIGEN; CP 870893; IDIOTYPIC ANTIBODY; IMMUNOGLOBULIN ANTIBODY; IMMUNOGLOBULIN G2; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG;

BIOASSAY; BLOOD SAMPLING; COMPETITIVE INHIBITION; CONCENTRATION RESPONSE; CONFERENCE PAPER; CULTURE MEDIUM; DAUDI CELL; DRUG RECEPTOR BINDING; HUMAN; HUMAN CELL; IMMUNE RESPONSE; MONKEY; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; QUANTITATIVE ASSAY; VALIDATION PROCESS;

MACACA FASCICULARIS;

EID: 33747619436     PISSN: 1547691X     EISSN: 1547691X     Source Type: Journal    
DOI: 10.1080/15476910600901535     Document Type: Conference Paper

References (10)

1. Eliopoulos, A. G., and Young, L. S. 2004. The role of the CD40 pathway in the pathogenesis and treatment of cancer. Curr. Opin. Pharmacol. 4:306-307.
2. Geng, D., Shanker, G., Schantz, A., Rajadhyaksha, M., Davis, H., and Wagner, C. 2005. Validation of immunoassays used to assess immunogenicity to therapeutic monoclonal antibodies. J. Pharm. Biomed. Anal. 39:264-275.
3. Hirano, A., Longo, D. L., Taub, D. D., Ferris, D. K., Young, L. S., Eliopoulos, A. G., Agathanggelou, A., Cullen, N., Macartney, J., Fanslow, W. C., and Murphy, W. J. 1999. Inhibition of human breast carcinoma growth by a soluble recombinant human CD40 ligand. Blood 93:2999-3007.
4. Mire-Sluis, A. R., Barrett, Y., Devanarayan, V., Koren, E., Liu, H., Maia, M., Parish, T., Shanker, G., Shores, E., Swanson, S. J., Taniguchi, G., Wierda, D., and Zuckerman, L. A. 2004. Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products. J. Immunol. Meth. 289:1-16.
5. Tong, A. W., and Stone, M. J. 2003. Prospects for CD40-directed experimental therapy of human cancer. Cancer Gene Ther. 10:1-13.
6. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, and Center for Biologics Evaluation and Research. 1997a. Guidance for Industry. S6 Preclinical Safety Evaluations of Biotechnology-Derived Pharmaceuticals. Available at (http://www.fda.gov/cber/guidelines.htm).
7. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, and Center for Biologics Evaluation and Research. 1997b. Points to Consider in the Manufacturing and Testing of Monoclonal Antibody Products for Human Use. Available at (http://www.fda.gov/cber/guidelines.htm).
8. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, and Center for Biologics Evaluation and Research. 2005. Guidance for Industry. Premarketing Risk Assessment. Available at (http://www.fda.gov/cber/guidelines.htm).
9. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, and Center for Biologics Evaluation and Research. 2006. Guidance for Industry. S8 Immunotoxicity Studies for Human Pharmaceuticals. Available at (http://www.fda.gov/cber/guidelines.htm).
10. Vonderheide R. H., Dutcher, J. P., Anderson, J. E., Eckhardt, S. G., Stephans, K. F., Razvillas, B., Garl, S., Buine, M. D., Perry, V. P., Armitage, R. J., Ghalie, R., Caron, D. A., and Gribben, J. G. 2001. Phase I study of recombinant human CD40 ligand in cancer patients. J. Clin. Oncol. 19:3280-3287.